In a murine model of bladder cancer in which tumors are induced by treatment with N-butyl-N-(4-hydroxybutyl) nitrosamine (BBN), genetic deletion of TXNIP results in accelerated development of high grade and invasive tumors by ~4 weeks compared to controls with wild-type expression, however, controls eventually succumb to tumor development and TXNIP expression in these tumors has been downregulated by other mechanisms [24]. The gene discussed is TXNIP; the disease is urinary bladder cancer.